Cargando…

Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET

Introduction: The gastrin-releasing peptide receptor (GRPR) is overexpressed in breast cancer. The present study evaluates GRPR imaging as a novel imaging modality in breast cancer by employing positron emission tomography (PET) and the GRPR antagonist (68)Ga-RM2. Methods: Fifteen female patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stoykow, Christian, Erbes, Thalia, Maecke, Helmut R, Bulla, Stefan, Bartholomä, Mark, Mayer, Sebastian, Drendel, Vanessa, Bronsert, Peter, Werner, Martin, Gitsch, Gerald, Weber, Wolfgang A, Stickeler, Elmar, Meyer, Philipp T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955063/ https://www.ncbi.nlm.nih.gov/pubmed/27446498 http://dx.doi.org/10.7150/thno.14958

Ejemplares similares

(68)Ga-Radiolabeling and Pharmacological Characterization of a Kit-Based Formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) Antagonist RM2 for Convenient Preparation of [(68)Ga]Ga-RM2
por: Chastel, Adrien, et al.
Publicado: (2021)

The effects of novel macrocyclic chelates on the targeting properties of the (68)Ga-labeled Gastrin releasing peptide receptor antagonist RM2
por: Wang, Yinwen, et al.
Publicado: (2023)

Gastrin-Releasing Peptide Receptor Antagonist [(68)Ga]RM2 PET/CT for Staging of Pre-Treated, Metastasized Breast Cancer
por: Michalski, Kerstin, et al.
Publicado: (2021)

Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist (68)Ga-RM2 and (18)F-FDG in breast cancer samples
por: Morgat, Clément, et al.
Publicado: (2019)

Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN(7–14) and Antagonist RM26
por: Cheng, Siyuan, et al.
Publicado: (2017)

First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist (68)Ga-NODAGA-MJ9
por: Gnesin, Silvano, et al.
Publicado: (2018)

Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker
por: Erbes, Thalia, et al.
Publicado: (2015)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

Imaging Properties and Tumor Targeting of (68)Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
por: Gruber, Leonhard, et al.
Publicado: (2022)

Radiochemistry and Preclinical PET Imaging of (68)Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen
por: Gourni, Eleni, et al.
Publicado: (2017)

Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men
por: Wieser, Gesche, et al.
Publicado: (2014)

Alternative splicing of synuclein gamma in endometrial cancer: identification of a novel isoform
por: Schaal, Kathrin, et al.
Publicado: (2015)

The somatostatin receptor 2 antagonist (64)Cu-NODAGA-JR11 outperforms (64)Cu-DOTA-TATE in a mouse xenograft model
por: Rylova, Svetlana N., et al.
Publicado: (2018)

Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection
por: Erbes, Thalia, et al.
Publicado: (2014)

HNRNP G and HTRA2-BETA1 regulate estrogen receptor alpha expression with potential impact on endometrial cancer
por: Hirschfeld, Marc, et al.
Publicado: (2015)

[(68)Ga]Ga-PSMA and [(68)Ga]Ga-RM2 PET/MRI vs. Histopathological Images in Prostate Cancer: A New Workflow for Spatial Co-Registration
por: Ghezzo, Samuele, et al.
Publicado: (2023)

[(68)Ga]Ga-RM2 PET/CT reveals small distant metastases not detected by conventional imaging in primary estrogen receptor-positive breast cancer
por: Michalski, Kerstin, et al.
Publicado: (2023)

CCKB/gastrin receptor antagonists: recent advances and potential uses in gastric secretory disorders.
por: Jensen, R. T.
Publicado: (1996)

Therapeutic effect of the gastrin receptor antagonist, CR2093 on gastrointestinal tumour cell growth.
por: Watson, S. A., et al.
Publicado: (1992)

Antiproliferative Effect of a Novel Cholecystokinin‐B/Gastrin Receptor Antagonist, YM022
por: Murayama, Tohru, et al.
Publicado: (1996)

(68)Ga-PSMA and (68)Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data
por: Mapelli, Paola, et al.
Publicado: (2022)

Structures of human gastrin-releasing peptide receptors bound to antagonist and agonist for cancer and itch therapy
por: Peng, Shuman, et al.
Publicado: (2023)

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics
por: Abouzayed, Ayman, et al.
Publicado: (2023)

The role of endogenous gastrin in the development of enterochromaffin-like cell carcinoid tumors in Mastomys natalensis: a study with the specific gastrin receptor antagonist AG-041R.
por: Chiba, T., et al.
Publicado: (1998)

Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of (68)Ga-PSMA and (68)Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients
por: Mapelli, Paola, et al.
Publicado: (2021)

Gastrin-releasing peptide receptor antagonist induces a protection from lethal sepsis: involvement of toll-like receptor 4 signaling
por: Petronilho, F, et al.
Publicado: (2010)

Results from extended lymphadenectomies with [(111)In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer
por: Jilg, Cordula A., et al.
Publicado: (2020)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Gastrin Receptor Gene Expression in Several Human Carcinomas
por: Matsushima, Yumi, et al.
Publicado: (1994)

Phase I Trial of [(99m)Tc]Tc-maSSS-PEG(2)-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors
por: Chernov, Vladimir, et al.
Publicado: (2023)

Preparation and preclinical evaluation of a (68)Ga-labelled c(RGDfK) conjugate comprising the bifunctional chelator NODIA-Me
por: Läppchen, Tilman, et al.
Publicado: (2018)

Cyclotron-based production of (68)Ga, [(68)Ga]GaCl(3), and [(68)Ga]Ga-PSMA-11 from a liquid target
por: Rodnick, Melissa E., et al.
Publicado: (2020)

Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications
por: Balafoutas, Dimitrios, et al.
Publicado: (2013)

Exometabolom analysis of breast cancer cell lines: Metabolic signature
por: Willmann, Lucas, et al.
Publicado: (2015)

Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference
por: Zamboglou, Constantinos, et al.
Publicado: (2018)

Meningiomas: A Comparative Study of (68)Ga-DOTATOC, (68)Ga-DOTANOC and (68)Ga-DOTATATE for Molecular Imaging in Mice
por: Soto-Montenegro, María Luisa, et al.
Publicado: (2014)

The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies
por: Smith, Jill P., et al.
Publicado: (2016)

Nanostrategies for Therapeutic and Diagnostic Targeting of Gastrin-Releasing Peptide Receptor
por: Rurarz, Beata Paulina, et al.
Publicado: (2023)

Value of (68)Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [(18)F]fluoromethylcholine PET-CT and multiparametric MRI—a phase I/II study
por: Beheshti, Mohsen, et al.
Publicado: (2022)

PSUN68 Finerenone for Primary Aldosteronism: A Novel Mineralocorticoid Receptor Antagonist
por: Aurora, John, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9lh1u6bcbad4po2m0tc7p05i5h